Evidence map›Paper›PMID 38556070›Full record

ArticleThe Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation2024

A multidimensional classifier to support lung transplant referral in patients with pulmonary fibrosis.

Janelle Vu Pugashetti, John S Kim, Michael P Combs, Shwu-Fan Ma, Ayodeji Adegunsoye, Angela L Linderholm, Mary E Strek, Ching-Hsien Chen, Daniel F Dilling, Timothy P M Whelan and 4 more

Open access · greenAbstract read
In one paragraph

Article in The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Proteomic Biomarkers of Survival in Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Disease.American journal of respiratory and critical care medicine · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 1 country.

Janelle Vu PugashettiDivision of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Michigan.
John S KimDivision of Pulmonary and Critical Care Medicine, University of Virginia, Charlottesville, Virginia.
Michael P CombsDivision of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Michigan.
Shwu-Fan MaDivision of Pulmonary and Critical Care Medicine, University of Virginia, Charlottesville, Virginia.
Ayodeji AdegunsoyeSection of Pulmonary and Critical Care Medicine, University of Chicago, Chicago, Illinois.
Angela L LinderholmDepartment of Internal Medicine, University of California Davis, Davis, California.
Mary E StrekSection of Pulmonary and Critical Care Medicine, University of Chicago, Chicago, Illinois.
Ching-Hsien ChenDepartment of Internal Medicine, University of California Davis, Davis, California.
Daniel F DillingDivision of Pulmonary and Critical Care Medicine, Loyola University Chicago, Stritch School of Medicine, Chicago, Illinois.
Timothy P M WhelanDivision of Pulmonary and Critical Care, Medical University of South Carolina, Charleston, South Carolina; Pulmonary Fibrosis Foundation, Chicago, Illinois.
Kevin R FlahertyDivision of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Michigan; Pulmonary Fibrosis Foundation, Chicago, Illinois.
Fernando J MartinezDivision of Pulmonary and Critical Care, Weill Cornell Medical Center, New York, New York.
Imre NothDivision of Pulmonary and Critical Care Medicine, University of Virginia, Charlottesville, Virginia.
Justin M OldhamDivision of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Michigan; Department of Epidemiology, University of Michigan, Ann Arbor, Michigan. Electronic address: oldhamj@med.umich.edu.
University of Michigan · USUniversity of Virginia · USUniversity of California, Davis · USUniversity of Chicago · USCornell University · USLoyola University Chicago · USMedical University of South Carolina · US

Funding

PULMONARY CELLULAR AND MOLECULAR BIOLOGY TRAININGT32HL007749 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Robert Pickett Dickson · 1993 to 2026
$19.9M
1/2 Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases studyUH3HL145266 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI MARTINEZ, FERNANDO J, NOTH, IMRE · 2021 to 2025
$11.6M
Proteomic Profiling of Idiopathic Pulmonary Fibrosis Progression TrajectoryR01HL169166 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Justin M Oldham · 2023 to 2026
$2.7M
Prognostic Biomarker Development in Progressive Fibrosing Interstitial Lung DiseaseR01HL166290 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Justin M Oldham · 2024 to 2026
$2.2M
Role of polyunsaturated fatty acids in pulmonary fibrosisK23HL150301 · NHLBI · UNIVERSITY OF VIRGINIA · PI KIM, JOHN S · 2021 to 2025
$858k
Improving Pulmonary Fibrosis Classification with Genomics Informed Phenotypic ClustersK23HL146942 · NHLBI · UNIVERSITY OF CHICAGO · PI ADEGUNSOYE, AYODEJI · 2020 to 2024
$810k
NHLBI NIH HHS K23 HL146942NHLBI NIH HHS K23 HL150301NHLBI NIH HHS R01 HL166290NHLBI NIH HHS R01 HL169166NHLBI NIH HHS T32 HL007749NHLBI NIH HHS UH3 HL145266
6 · The paper itself

Abstract

backgroundLung transplantation remains the sole curative option for patients with idiopathic pulmonary fibrosis (IPF), but donor organs remain scarce, and many eligible patients die before transplant. Tools to optimize the timing of transplant referrals are urgently needed.

methodsLeast absolute shrinkage and selection operator was applied to clinical and proteomic data generated as part of a prospective cohort study of interstitial lung disease (ILD) to derive clinical, proteomic, and multidimensional logit models of near-term death or lung transplant within 18 months of blood draw. Model-fitted values were dichotomized at the point of maximal sensitivity and specificity, and decision curve analysis was used to select the best-performing classifier. We then applied this classifier to independent IPF and non-IPF ILD cohorts to determine test performance characteristics. Cohorts were restricted to patients aged ≤72 years with body mass index 18 to 32 to increase the likelihood of transplant eligibility.

resultsIPF derivation, IPF validation, and non-IPF ILD validation cohorts consisted of 314, 105, and 295 patients, respectively. A multidimensional model comprising 2 clinical variables and 20 proteins outperformed stand-alone clinical and proteomic models. Following dichotomization, the multidimensional classifier predicted near-term outcome with 70% sensitivity and 92% specificity in the IPF validation cohort and 70% sensitivity and 80% specificity in the non-IPF ILD validation cohort.

conclusionsA multidimensional classifier of near-term outcomes accurately discriminated this end-point with good test performance across independent IPF and non-IPF ILD cohorts. These findings support refinement and prospective validation of this classifier in transplant-eligible individuals.

Indexed as

Idiopathic Pulmonary FibrosisLung TransplantationReferral and ConsultationAgedFemaleHumansMaleMiddle AgedProspective StudiesProteomicsbiomarkeridiopathic pulmonary fibrosisinterstitial lung diseaseproteomicssurvival

Identifiers

PMID38556070
PMCPMC11451110
OpenAlexW4393313073

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.